Completed
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
NCT01474421
- Conditions
- Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +11 more
- Locations
-
- Novartis Investigative Site Sacramento, California, United States
- Novartis Investigative Site Manhasset, New York, United States
- Novartis Investigative Site Cincinnati, Ohio, United States
- Novartis Investigative Site Cleveland, Ohio, United States